Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 5/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | CD63 | P08962 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.35 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23108619 | 1.00 | ADORA2A (0.41) | ADORA2AADORA1SYKACACBCHEK1 | |
| SCHEMBL23102759 | 0.86 | PDK1 (0.41) | SYKACACBLRRK2CHRNB2CHRNA4 | |
| SCHEMBL23133581 | 0.86 | PDK1 (0.41) | SYKACACBLRRK2CHRNB2CHRNA4 | |
| SCHEMBL25147359 | 0.86 | SYK (0.41) | ADORA2AADORA1SYKACACBCHEK1 | |
| SCHEMBL23103857 | 0.86 | SYK (0.41) | ADORA2AADORA1SYKACACBCHEK1 | |
| SCHEMBL23114770 | 0.86 | SYK (0.41) | ADORA2AADORA1SYKACACBCHEK1 | |
| SCHEMBL23132897 | 0.83 | ACACB (0.39) | ACACBCHEK1CHRNB2CHRNA4HDAC6 | |
| SCHEMBL23132889 | 0.83 | ACACB (0.39) | ACACBCHEK1CHRNB2CHRNA4HDAC6 | |
| SCHEMBL20457829 | 0.82 | ADORA2A (0.41) | ADORA2AADORA1SYKCHEK1LRRK2 | |
| SCHEMBL23132316 | 0.82 | CHEK1 (0.44) | ADORA2AADORA1SYKCHEK1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548890-B1 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548890-B1 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | ADORA2A 4172/4885ADORA1 4414/4885SYK 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.